All In Biotech

Drug Trial Radar · NCT05234580

Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis

A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

204

Actual

Start

Apr 15, 2022

Primary completion

Oct 10, 2022

Study completion Dec 25, 2022

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Nasal Spray in patients with seasonal allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

  • PA9159 nasal spray solution, 10 μg once daily for 14 daysDrug

    PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

  • PA9159 nasal spray solution, 20 μg once daily for 14 daysDrug

    PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

  • PA9159 nasal spray solution, 40 μg once daily for 14 daysDrug

    PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

  • Placebo nasal spray solution without PA9159, once daily for 14 daysDrug

    Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation the change from baseline in daily subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) averaged over the 14-day treatment period.Time frame: From pre-dose until 14 days post-dose

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Shijitan Hospital

    Beijing, Beijing Municipality, China

  • Beijing TongRen Hospital

    Beijing, Beijing Municipality, China

  • Dongfang Hospital Beijing University of Chinese Medicine

    Beijing, Beijing Municipality, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The Affiliated Hospital of Changchun University of Chinese Medicine

    Changchun, Jilin, China

  • Tonghua Central Hospital

    Tonghua, Jilin, China

  • Yanbian University Hospital(Yanbian Hospital)

    Yanji, Jilin, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Zibo Central Hospital

    Zibo, Shandong, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.